At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate

    At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical
     Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients

Nearly Half of Current Non-Prescribers Anticipate Prescribing Xofigo in the
Next Four to Six Months, According to a New Report from BioTrends Research

PR Newswire

EXTON, Pa., Sept. 16, 2013

EXTON, Pa., Sept. 16, 2013 /PRNewswire/ --BioTrends Research Group, one of
the world's leading research and advisory firms for specialized
biopharmaceutical issues, finds that, at one month post-launch of Algeta/Bayer
HealthCare's Xofigo in the United States, approximately one quarter of
surveyed U.S. medical oncologists indicated that they have prescribed Xofigo.
According to the first wave of the LaunchTrends^® Xofigo report series, nearly
half of current non-prescribers stated that they would prescribe Xofigo in the
next four to six months. Notably, the majority of current non-prescribers
indicated that they would prescribe Xofigo to both their docetaxel-naive and
docetaxel-pretreated metastatic castrate-resistant prostate cancer (mCRPC)


The report also finds that over half of surveyed medical oncologists reported
high favorability toward Xofigo, and a majority of respondents indicated a
high level of interest in Xofigo. For docetaxel-naive mCRPC, the highest
proportion of surveyed medical oncologists indicated that the bone-targeted
mechanism of action of Xofigo and its safety profile are among the main
advantages of the agent. For docetaxel-pretreated mCRPC, the main perceived
advantages of Xofigo over Johnson & Johnson/Janssen Biotech/Janssen-Cilag's
Zytiga and Medivation/Astellas Pharma's Xtandi lie in Xofigo's limited and
fixed treatment duration and the fact that it is an efficacious bone-targeted
agent, according to surveyed medical oncologists.

"Surveyed medical oncologists cited the need to refer patients to a licensed
nuclear medicine facility as one of the main disadvantages of Xofigo compared
to other agents used to treat docetaxel-naive and docetaxel-pretreated mCRPC,"
said Decision Resources Group Senior Business Insights Analyst Khurram Nawaz,
M.Sc. "We also find that just over half of Xofigo non-prescribers indicated
that they are aware of the nearest location licensed for Xofigo

LaunchTrends: Xofigo (US) is a three-wave syndicated report series designed to
track the uptake of Xofigo at one month, six months and one year following
Xofigo's commercial availability, based upon primary research with U.S.
medical oncologists. LaunchTrends assess trial and use of new products,
obstacles to use, reasons to use, typical patient types, line of therapy,
product perceptions, promotional efforts/messages and product satisfaction.
For this first wave of research, BioTrends surveyed 75 U.S. medical
oncologists and conducted qualitative interviews with 13 U.S. medical
oncologists in July 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please visit BioTrends is a
Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE BioTrends Research Group

Press spacebar to pause and continue. Press esc to stop.